- Home
- TSHA vs ESPR Comparison
TSHA vs ESPR Comparison
Compare TSHA & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- ESPR
- Stock Information
- Founded
- TSHA 2019
- ESPR 2008
- Country
- TSHA United States
- ESPR United States
- Employees
- TSHA N/A
- ESPR N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- TSHA Health Care
- ESPR Health Care
- Exchange
- TSHA Nasdaq
- ESPR Nasdaq
- Market Cap
- TSHA 334.1M
- ESPR 305.0M
- IPO Year
- TSHA 2020
- ESPR 2013
- Fundamental
- Price
- TSHA $1.72
- ESPR $1.50
- Analyst Decision
- TSHA Strong Buy
- ESPR Buy
- Analyst Count
- TSHA 8
- ESPR 7
- Target Price
- TSHA $6.63
- ESPR $6.36
- AVG Volume (30 Days)
- TSHA 1.5M
- ESPR 3.5M
- Earning Date
- TSHA 02-26-2025
- ESPR 03-04-2025
- Dividend Yield
- TSHA N/A
- ESPR N/A
- EPS Growth
- TSHA N/A
- ESPR N/A
- EPS
- TSHA N/A
- ESPR N/A
- Revenue
- TSHA $8,333,000.00
- ESPR $332,314,000.00
- Revenue This Year
- TSHA N/A
- ESPR $5.51
- Revenue Next Year
- TSHA N/A
- ESPR $1.42
- P/E Ratio
- TSHA N/A
- ESPR N/A
- Revenue Growth
- TSHA N/A
- ESPR 185.66
- 52 Week Low
- TSHA $1.19
- ESPR $1.47
- 52 Week High
- TSHA $4.32
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- TSHA 54.31
- ESPR 34.95
- Support Level
- TSHA $1.66
- ESPR $1.57
- Resistance Level
- TSHA $1.77
- ESPR $1.86
- Average True Range (ATR)
- TSHA 0.11
- ESPR 0.13
- MACD
- TSHA 0.01
- ESPR -0.01
- Stochastic Oscillator
- TSHA 47.62
- ESPR 7.69
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.